Difference between revisions of "Cytarabine liposomal (DepoCyt)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
m |
||
| Line 7: | Line 7: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[CNS leukemia]] | ||
| + | *[[CNS lymphoma]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 27: | Line 31: | ||
[[Category:Irritant chemotherapy]] | [[Category:Irritant chemotherapy]] | ||
| + | |||
| + | [[Category:CNS leukemia medications]] | ||
| + | [[Category:CNS lymphoma medications]] | ||
[[Category:FDA approved in 1999]] | [[Category:FDA approved in 1999]] | ||
Revision as of 23:44, 22 August 2018
General information
Class/mechanism: Pyrimidine analog, mimics cytosine. Converted intracellularly into cytarabine-5-triphosphate (ara-CTP). Exact mechanism of action not known; believed to inhibit DNA polymerase, incorporate into DNA and RNA, and kill cells undergoing DNA synthesis (S-phase) and sometimes block cells from progressing from the G1 phase to the S-phase.[1][2][3]
Route: IT
Extravasation: irritant
- "In-line filters must not be used when administering DepoCyt."[1]
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)[4]
- Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)[5]
Also known as
- Generic name: Liposomal Ara-C
- Brand name: Depocyt
References
- ↑ 1.0 1.1 1.2 Cytarabine liposomal (DepoCyt) package insert
- ↑ Cytarabine liposomal (DepoCyt) package insert (locally hosted backup)
- ↑ Depocyt manufacturer's website
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (Chemocare)
- ↑ Cytarabine liposomal (DepoCyt) patient drug information (UpToDate)